SUMMARY OF CLINICAL GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF OSTEOPOROSIS OF THE RUSSIAN ASSOCIATION OF ENDOCRINOLOGISTS
https://doi.org/10.14341/osteo2016328-36
Abstract
Представлено краткое изложение клинических рекомендаций по диагностике и лечению остеопороза, разработанных членами Российской ассоциации эндокринологов при участии членов Российской ассоциации по остеопорозу (ревматологов, травматологов, терапевтов, гинекологов-эндокринологов). Рекомендации разработаны с позиций доказательной медицины, в соответствии с требованиями к составлению клинических рекомендаций Минздрава России, опубликованными в 2016 г. Значительное место в изложении отведено диагностике остеопороза у взрослых, дифференциальной диагностике с другими метаболическими заболеваниями скелета, а также принципам патогенетического лечения остеопороза. Клинические рекомендации полезны будут как врачам общей практики, так и специалистам, прежде всего эндокринологам, ревматологам, травматологам-ортопедам, гинекологам, нефрологам, гастроэнднрологам и неврологам, так как остеопороз является мультифакториальным и мультидисциплинарным заболеванием
About the Authors
G A MelnichenkoZh E Belaya
L Ya Rozhinskaya
T A Grebennikova
E A Pigarova
N V Toroptsova
O A Nikitinskaya
L Ya Farba
N V Tarbaeva
T O Chernova
L K Dzeranova
A V Ilyin
S V Yureneva
I V Kryukova
E O Mamedova
E V Biryukova
N V Zagorodny
S S Rodionova
O M Lesniak
I A Skripnikova
A V Dreval
L A Alekseeva
I I Dedov
References
1. Kanis J.A., on behalf of the WHO Scientific Group. Assessment of osteoporosis at the primary health-care level. Technical Report. WHO Collaboraiting Centre, University of Sheffield, UK, 2008.
2. Евстигнеева Л.П., Солодовников А.Г., Ершова О.Б., Белова К.Ю., Зоткин Е.Г., Чернова Т.О., Смирнов А.В., Скрипникова И.А., Поддубская Е.А., Косматова О.В., Новиков В.Е., Смирнов А.В., Ермакова И.П., Пронченко И.А., Зоткин Е.Г., Торопцова Н.В., Баранова И.А., Аникин С.Г., Марченкова Л.А., Крюкова ИВ, Зазерская И.Е., Коновалова В.Н., Кузнецова Л.В., Сметник В.П., Юренева С.В., Белая Ж.Е., Рожинская Л.Я., Баранова И.А., Дыдыкина И.С., Лесняк О.М., Беневоленская Л.И. Остеопороз. Диагностика, профилактика и лечение Москва, 2010. Клинические рекомендации (Второе издание, переработанное и дополненное).
3. Camacho P.M., Petak S.M., Binkley N., Clarke B.L., Harris S.T., Hurley D.L., Kleerekoper M., Lewiecki E.M., Miller P.D., Narula H.S., Pessah-Pollack R., Tangpricha V., Wimalawansa S.J., Watts N.B.: American association of clinical endocrinologists and American college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis - 2016.Endocr Pract. 2016 Sep 2; 22(Suppl 4): 1-42.
4. Kanis J., McCloskey E., Johansson H., Cooper C., Rizzoli R., Reginster J. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporosis International. 2013; 24(1): 23-57. doi: 10.1007/s00198-012-2074-y.
5. Raman-Wilms L. Book Review: Guidelines for Preclinical Evaluation and Clinical Trials in Osteoporosis. Annals of Pharmacotherapy. 1999; 33(12): 1377-1378. doi: 10. 1177/106002809903301207.
6. American Association of Orthopedic Surgeon Position Statement, 1159, December 2009.
7. Лесняк О.М., Ершова О.Б. Аудит состояния проблемы остеопороза в странах Восточной Европы и Центральной Азии 2010. Naturaprint; 2011.
8. Дедов И.И., Мельниченко Г.А., Белая Ж.Е., Рожинская Л.Я.: «Остеопороз - от редкого симптома эндокринных болезней до безмолвной эпидемии 20-21 века» // Проблемы Эндокринологии, 2011, том 57. Стр. 35-45.
9. Ершова О.Б., Белова К.Ю., Белов М.В., Ганерт О.А., Гладкова Е.Н., Ходырев В.Н., Лесняк О.М., Давтян В.Г., Пилюкова Р.И., Романова М.А., Синицина О.С Эпидемиология переломов проксимального отдела бедренной кости у городского населения Российской Федерации: результаты многоцентрового исследования. Форум остеопороза, 23-25 сентября, 2012; Санкт-Петербург. Материалы научно-практической конференции «Остеопороз - важнейшая мультидисциплинарная проблема здравоохранения XXI века»; 23-27.
10. Меньшикова Л.В., Храмцова Н.А., Ершова О.Б. Ближайшие и отдаленные исходы переломов проксимального отдела бедра у лиц пожилого возраста и их медикосоциальные последствия (по данным многоцентрового исследования) // Остеопороз и остеопатии. 2002; 1: 8-11.
11. Добровольская О.В. Осложненный остеопороз: минеральная плотность костной ткани различных отделов скелета, качество жизни, приверженность терапии и затраты на лечение: автореферат дис.. кандидата медицинских наук: 14.01.22. - Москва, 2016. - 22 с. Ревматология 9 16-14/862.
12. Kanis J., Johnell O., Oden A., Johansson H., McCloskey E. FRAX™ and the assessment of fracture probability in men and women from the UK. Osteoporosis International. 2008; 19(4): 385-397. doi: 10.1007/s00198-007-0543-5.
13. Burch J., Rice S., Yang H. et al. Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups. Health Technology Assessment. 2014; 18(11). doi: 10.3310/hta18110.
14. Bergmann P., Body J., Boonen S. et al. Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club. International Journal of Clinical Practice. 2009; 63(1): 19-26. doi: 10.1111/j.1742-1241.2008.01911.x.
15. Ravn P., Hosking D., Thompson D. et al. Monitoring of Alendronate Treatment and Prediction of Effect on Bone Mass by Biochemical Markers in the Early Postmenopausal Intervention Cohort Study1. The Journal of Clinical Endocrinology & Metabolism. 1999; 84(7): 2363-2368. doi: 10.1210/jcem.84.7.5847.
16. Fink E., Cormier C., Steinmetz P., Kindermans C., Le Bouc Y., Souberbielle J. Differences in the Capacity of Several Biochemical Bone Markers to Assess High Bone Turnover in Early Menopause and Response to Alendronate Therapy. Osteoporosis International. 2000; 11(4): 295-303. doi: 10.1007/ pl00004183.
17. Bauer D., Black D., Garnero P. et al. Change in Bone Turnover and Hip, Non-Spine, and Vertebral Fracture in Alendronate-Treated Women: The Fracture Intervention Trial. J Bone Miner Res. 2004; 19(8): 1250-1258. doi: 10.1359/jbmr.040512.
18. Eastell R., Barton I., Hannon R., Chines A., Garnero P., Delmas P. Relationship of Early Changes in Bone Resorption to the Reduction in Fracture Risk With Risedronate. J Bone Miner Res. 2003; 18(6): 1051-1056. doi: 10.1359/jbmr.2003.18.6.1051.
19. Delmas P., Recker R., Chesnut C. et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporosis International. 2004; 15(10). doi: 10.1007/s00198-004-1602-9.
20. Reginster JGieschke R. Clinical Utility of a Pharmacostatistical Model for Ibandronate in Postmenopausal Osteoporosis. CDM. 2006; 7(7): 827-836. doi: 10.2174/138920006778520624.
21. Krege J., Lane N., Harris J., Miller P. PINP as a biological response marker during teriparatide treatment for osteoporosis. Osteoporosis International. 2014; 25(9): 2159-2171. doi: 10.1007/s00198-014-2646-0.
22. Imaz I., Zegarra P., Gonzalez-Enriquez J., Rubio B., Alcazar R., Amate J. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporosis International. 2009; 21(11): 1943-1951. doi: 10.1007/s00198-009-1134-4.
23. Dresner-Pollak R., Parker R., Poku M., Thompson J., Seibel M., Greenspan S. Biochemical Markers of Bone Turnover Reflect Femoral Bone Loss in Elderly Women. Calcified Tissue International. 1996; 59(5): 328-333. doi: 10.1007/s002239900135.
24. Ross PKnowlton W. Rapid Bone Loss Is Associated with Increased Levels of Biochemical Markers. J Bone Miner Res. 1998; 13(2): 297-302. doi: 10.1359/jbmr.1998.13.2.297.
25. Hansen M.A., Overgaard K., Riis B.J. et al. Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12 year study. BMJ 1991; 303: 961-4.
26. Garnero P., Sornay-Rendu E., Duboeuf F., Delmas P. Markers of Bone Turnover Predict Postmenopausal Forearm Bone Loss Over 4 Years: The OFELY Study. J Bone Miner Res. 1999; 14(9): 1614-1621. doi: 10.1359/jbmr.1999.14.9.1614.
27. Boonen S., Body J., Boutsen Y. et al. Evidence-based guidelines for the treatment of postmenopausal osteoporosis: a consensus document of the Belgian Bone Club. Osteoporosis International. 2005; 16(3): 239-254. doi: 10.1007/s00198-004-1812-1.
28. Schousboe J., Bauer D., Nyman J., Kane R., Melton L., Ensrud K. Potential for bone turnover markers to cost-effectively identify and select post-menopausal osteopenic women at high risk of fracture for bisphosphonate therapy. Osteoporosis International. 2006; 18(2): 201-210. doi: 10.1007/s00198-006-0218-7.
29. McNabb B., Vittinghoff E., Schwartz A. et al. BMD changes and predictors of increased bone loss in postmenopausal women after a 5-year course of alendronate. J Bone Miner Res. 2013; 28(6): 1319-1327. doi: 10.1002/jbmr.1864.
30. Bauer D., Schwartz A., Palermo L. et al. Fracture Prediction After Discontinuation of 4 to 5 Years of Alendronate Therapy. JAMA Internal Medicine. 2014; 174(7): 1126.
31. Cosman F., Cauley J., Eastell R. et al. Reassessment of Fracture Risk in Women After 3 Years of Treatment With Zoledronic Acid: When is it Reasonable to Discontinue Treatment?. The Journal of Clinical Endocrinology & Metabolism. 2014; 99(12): 4546-4554. doi: 10.1210/jc.2014-1971.
32. Bauer D., Garnero P., Hochberg M. et al. Pretreatment Levels of Bone Turnover and the Antifracture Efficacy of Alendronate: The Fracture Intervention Trial. J Bone Miner Res. 2005; 21(2): 292-299. doi: 10.1359/jbmr.051018.
33. Seibel M., Naganathan V., Barton I., Grauer A. Relationship Between Pretreatment Bone Resorption and Vertebral Fracture Incidence in Postmenopausal Osteoporotic Women Treated With Risedronate. J Bone Miner Res. 2003; 19(2): 323-329. doi: 10.1359/jbmr.0301231.
34. Cosman F., de Beur S., LeBoff M., de Beur S.J., Tanner B. Clinician’s Guide to Prevention and Treatment of Osteoporosis. National Osteoporosis Foundation 1150 17th St., NW, Suite 850, Washington, DC 20036, Release Date: April 1, 2014.
35. Ross P. Pre-Existing Fractures and Bone Mass Predict Vertebral Fracture Incidence in Women. Annals of Internal Medicine. 1991; 114(11): 919. doi: 10.7326/0003-4819-114-11-919.
36. Kanis J., Melton L., Christiansen C., Johnston C., Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res. 2009; 9(8): 1137-1141. doi: 10.1002/jbmr.5650090802.
37. Genant H.K., Jergas M. Assessment of prevalent and incident vertebral fractures in osteoporosis research. Osteoporosis Int. 2003; 14(3): 43-55.
38. Yamamoto M., Yamaguchi T., Yamauchi M., Kaji H., Sugimoto T. Diabetic patients have an increased risk of vertebral fractures independent of BMD or diabetic complications.J Bone Miner Res. 2009 Apr; 24(4): 702-9. doi: 10.1359/jbmr.081207.
39. Dede A.D., Tournis S., Dontas I., Trovas G. Type 2 diabetes mellitus and fracture risk. Metabolism. 2014 Dec; 63(12): 1480-90. doi: 10.1016/j.metabol.2014.09.002.
40. Schousboe J., Ensrud K., Nyman J., Kane R., Melton L. Potential cost-effective use of spine radiographs to detect vertebral deformity and select osteopenic post-menopausal women for amino-bisphosphonate therapy. Osteoporosis International. 2005; 16(12): 1883-1893. doi: 10.1007/s00198-005-1956-7.
41. Genant H., Wu C., van Kuijk C., Nevitt M. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res. 2009; 8(9): 1137-1148. doi: 10.1002/jbmr.5650080915.
42. Kazawa N. T2WI MRI and MRI-MDCT correlations of the osteoporotic vertebral compressive fractures. European Journal of Radiology. 2012; 81(7): 1630-1636. doi: 10.1016/j.ejrad.2011.04.052.
43. Baum T., Karampinos D., Liebl H., Rummeny E., Waldt S., Bauer J. High-Resolution Bone Imaging for Osteoporosis Diagnostics and Therapy Monitoring Using Clinical MDCT and MRI. CMC. 2013; 20(38): 4844-4852. doi: 10.2174/09298 673113206660279.
44. Kanis J., Johnell O., De Laet C., Jonsson B., Oden A., Ogelsby A. International Variations in Hip Fracture Probabilities: Implications for Risk Assessment. J Bone Miner Res. 2002; 17(7): 1237-1244. doi: 10.1359/jbmr.2002.17.7.1237.
45. De Laet C., Van Hout B., Burger H., Weel A., Hofman A., Pols H. Hip Fracture Prediction in Elderly Men and Women: Validation in the Rotterdam Study. J Bone Miner Res. 2009; 13(10): 1587-1593. doi: 10.1359/jbmr.1998.13.10.1587.
46. Kanis J., Bianchi G., Bilezikian J. et al. Towards a diagnostic and therapeutic consensus in male osteoporosis. Osteoporosis International. 2011; 22(11): 2789-2798. doi: 10.1007/s00198-011-1632-z.
47. Kanis J.A., Harvey N.C., Cooper C. et al. A systematic review of intervention thresholds based on FRAX: A report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation. Arch Osteoporos. 2016 Dec; 11(1): 25. doi: 10.1007/s11657-016-0278-z.
48. Lewiecki E., Watts N., McClung M. et al. Official Positions of the International Society for Clinical Densitometry. The Journal of Clinical Endocrinology & Metabolism. 2004; 89(8): 3651-3655. doi: 10.1210/jc.2004-0124.
49. Lesnyak O., Ershova O., Belova K. et al. Epidemiology of fracture in the Russian Federation and the development of a FRAX model. Arch Osteoporos. 2012; 7(1-2): 67-73. doi: 10.1007/s11657-012-0082-3.
50. Алексеева Л.И., Баранова И.А., Белова К.Ю., Ершова О.Б., Зазерская И.Е., Зоткин Е.Г, Лесняк О.М., Никитинская О.А., Рожинская Л.Я., Скрипникова И.А., Смирнов А.В., Щеплягина Л.А.: Клинические рекомендации по профилактике и ведению больных с остеопорозом под редакцией О.М. Лесняк. Литера;. Ярославль, 2012: 23.
51. Никитинская О.А., Торопцова Н.В. Оценка риска переломов с использованием модели FRAX® (ретроспективное десятилетнее исследование) Альманах клинической медицины. 2014; 43: 50-55.
52. National Osteoporosis Foundation (NOF) and International Society for Clinical Densitometry (ISCD). Recommendations to DXA Manufacturers for FRAX® Implementation. Available http://www.nof.org/files/nof/public/content/resource/862/files/392.pdf. Accessed January 28, 2013
53. Management of postmenopausal osteoporosis: position statement of The North American Menopause Society. Menopause. 2002: 84-101. doi: 10.1097/00042192-200203000-00003.
54. ISCD positions. Journal of Clinical Densitometry. 2004; 7(1).
55. Official Positions of the International Society for Clinical Densitometry. Copyright ISCD, October 2007.
56. Nelson H.D., Haney E.M., Chou R., Dana T., Fu R., Bougatsos C. Screening for Osteoporosis: Systematic Review to Update the 2002 US Preventive Services Task Force Recommendation. Rockville (MD): Agency for Healthcare Research and Quality (US); 2010 Jul. Report No.: 10-05145-EF-1.
57. Bonnick S. Bone Densitometry in Clinical Practice. Humana Press Inc. 2004: 411.
58. McCloskey E., Odén A., Harvey N. et al. A meta-analysis of trabecular bone score in fracture risk prediction and its relationship to FRAX. J Bone Miner Res. 2015: n/a-n/a. doi: 10.1002/jbmr.2734.
59. Bousson V., Bergot C., Sutter B., Levitz P., Cortet B. Trabecular bone score (TBS): available knowledge, clinical relevance, and future prospects. Osteoporosis International. 2011; 23(5): 1489-1501. doi: 10.1007/s00198-011-1824-6.
60. International Society for Clinical Densitometry. 2013 Official Positions - Adult. http://www.iscd.org/official-positions/2013-iscd-official-positions-adult. Ссылка активна на 05.05.2016.
61. Black D.M., Cummings S.R., Karpf D.B. et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996; 348: 1535-1541.
62. Black D., Delmas P., Eastell R. et al. Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis. N Engl J Med. 2007 May 3; 356(18): 1809-22 DOI: 10.1056/NEJMoa067312.
63. Cummings S.R., Black D.M., Thompson D.E. et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998; 280: 2077-2082. doi: 10.1001/jama.280.24.2077
64. Cummings S., Martin J., McClung M. et al. Denosumab for Prevention of Fractures in Postmenopausal Women With Osteoporosis. N Engl J Med. 2009 Aug 20; 361(8): 756-65. doi: 10.1056/NEJMoa0809493. Epub 2009 Aug 11.
65. Saag K., Emkey R., Schnitzer T. et al. Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Obstetrical & Gynecological Survey. 1999; 54(1): 39-40. doi: 10.1097/00006254-199901000-00021
66. Boonen S., Orwoll E., Wenderoth D., Stoner K., Eusebio R., Delmas P. Once-Weekly Risedronate in Men With Osteoporosis: Results of a 2-Year, Placebo-Controlled, Double-Blind, Multicenter Study. Journal of Bone and Mineral Research. 2009; 24(4): 719-725. doi: 10.1359/jbmr.081214
67. Eastell R., Devogelaer J., Peel N. et al. Prevention of Bone Loss with Risedronate in Glucocorticoid-Treated Rheumatoid Arthritis Patients. Osteoporosis International. 2000; 11(4): 331-337. doi: 10.1007/s001980070122
68. Hakala M., Kröger H., Valleala H. et al. Once-monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases: a 12-month, randomized, double-blind, placebo-controlled trial. Scandinavian Journal of Rheumatology. 2012; 41(4): 260-266. doi: 10.3109/03009742.2 012.664647
69. Cranney A., Wells G., Yetisir E. et al. Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporosis International. 2008; 20(2): 291-297. doi: 10.1007/s00198-008-0653-8
70. Harris S., Blumentals W., Miller P. Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Current Medical Research and Opinion. 2007; 24(1): 237-245. doi: 10.1185/030079908x253717
71. Boonen S., Reginster J., Kaufman J. et al. Fracture Risk and Zoledronic Acid Therapy in Men with Osteoporosis. New England Journal of Medicine. 2012; 367(18): 1714-1723
72. Shane E., Burr D., Abrahamsen B. et al. Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2013; 29(1): 1-23. doi: 10.1002/jbmr.1998
73. Kenneth W. Lyles, M.D., Cathleen S. Colôn-Emeric, M.D., M.H.Sc., Jay S. Magaziner, Ph.D., Jonathan D. Adachi, M.D., Carl F. Pieper, D.P.H., Carlos Mautalen, M.D., Lars Hyldstrup, M.D., D.M.Sc., Chris Recknor, M.D., Lars Nordsletten, M.D., Ph.D., Kathy A. Moore, R.N., Catherine Lavecchia, M.S., Jie Zhang, Ph.D., Peter Mesenbrink, Ph.D., Patricia K. Hodgson, B.A., Ken Abrams, M.D., John J. Orloff, M.D., Zebulun Horowitz, M.D., Erik Fink Eriksen, M.D., D.M.Sc., and Steven Boonen, M.D., Ph.D., for the HORIZON Recurrent Fracture Trial*Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture. N Engl J Med. 2007; 357: 1799-1809
74. McClung M, Miller P, Recknor C, Mesenbrink P, Bucci-Rechtweg C, Benhamou C. Zoledronic Acid for the Prevention of Bone Loss in Postmenopausal Women With Low Bone Mass. Obstetrics & Gynecology. 2009; 114(5): 999-1007. doi: 10.1097/aog.0b013e3181bdce0a
75. Langdahl B., Teglbjærg C., Ho P. et al. A 24-Month Study Evaluating the Efficacy and Safety of Denosumab for the Treatment of Men With Low Bone Mineral Density: Results From the ADAMO Trial. The Journal of Clinical Endocrinology & Metabolism. 2015; 100(4): 1335-1342. doi: 10.1210/jc.2014-4079
76. Orwoll E., Teglbjærg C., Langdahl B. et al. A Randomized, Placebo-Controlled Study of the Effects of Denosumab for the Treatment of Men with Low Bone Mineral Density. The Journal of Clinical Endocrinology & Metabolism. 2012; 97(9): 3161-3169. doi: 10.1210/jc.2012-1569
77. Gnant M., Pfeiler G., Dubsky P. et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. The Lancet. 2015; 386(9992): 433-443. doi: 10.1016/s0140-6736(15)60995-3
78. McClung M. Inhibition of RANKL as a treatment for osteoporosis: Preclinical and early clinical studies. Current Osteoporosis Reports. 2006; 4(1): 28-33. doi: 10.1007/s11914-006-0012-7
79. Miller P., Bolognese M., Lewiecki E. et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial. Bone. 2008; 43(2): 222-229. doi: 10.1016/j.bone.2008.04.007
80. Белая Ж.Е., Рожинская Л.Я. Новые направления в терапии остеопороза - применение моноклональных человеческих антител к RANKL (Деносумаб). // Остеопороз и Остеопатии. 2011; 2: 19-22
81. Brown J., Prince R., Deal C. et al. Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial*. Journal of Bone and Mineral Research. 2009; 24(1): 153-161. doi: 10.1359/jbmr.0809010.
82. Mandema J.W.1, Zheng J., Libanati C., Perez Ruixo J.J. Time course of bone mineral density changes with denosumab compared with other drugs in postmenopausal osteoporosis: a dose-response-based meta-analysis.J Clin Endocrinol Metab. 2014 Oct; 99(10): 3746-55. doi: 10.1210/jc.2013-3795. Epub 2014 Jun 10.
83. Choi N.K., Solomon D.H., Tsacogianis T.N., Landon J.E., Song H.J., Kim S.C. Comparative Safety and Effectiveness of Denosumab Versus Zoledronic Acid in Patients With Osteoporosis: A Cohort Study. J Bone Miner Res. 2016 Oct 13. doi: 10.1002/jbmr.3019. [Epub ahead of print]
84. Kendler D., Roux C., Benhamou C. et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res. 2009; 25(1): 72-81. doi: 10.1359/jbmr.090716.
85. Tsai.J, Uihlein A., Burnett-Bowie S. et al. Comparative Effects of Teriparatide, Denosumab, and Combination Therapy on Peripheral Compartmental Bone Density, Microarchitecture, and Estimated Strength: the DATA-HRpQCT Study. J Bone Miner Res. 2014; 30(1): 39-45. doi: 10.1002/jbmr.2315.
86. Белая Ж.Е., Рожинская Л.Я. Анаболическая терапия остеопороза. Терипаратид: эффективность, безопасность и область применения. Остеопороз и остеопатии. 2013; 2: 32-40.
87. Gallagher J., Genant H., Crans G., Vargas S., Krege J. Teriparatide Reduces the Fracture Risk Associated with Increasing Number and Severity of Osteoporotic Fractures. The Journal of Clinical Endocrinology & Metabolism. 2005; 90(3): 1583-1587. doi: 10.1210/jc.2004-0826.
88. Marcus R., Wang O., Satterwhite J., Mitlak B. The Skeletal Response to Teriparatide Is Largely Independent of Age, Initial Bone Mineral Density, and Prevalent Vertebral Fractures in Postmenopausal Women With Osteoporosis. J Bone Miner Res. 2003; 18(1): 18-23. doi: 10.1359/jbmr.2003.18.1.18.
89. Orwoll E., Scheele W., Paul S. et al. The Effect of Teriparatide [Human Parathyroid Hormone (1-34)] Therapy on Bone Density in Men With Osteoporosis. J Bone Miner Res. 2003; 18(1): 9-17. doi: 10.1359/jbmr.2003.18.1.9.
90. Saag K., Shane E., Boonen S. et al. Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis. N Engl J Med. 2007 Nov 15; 357(20): 2028-39 DOI: 10.1056/NEJMoa071408
91. Saag K., Zanchetta J., Devogelaer J. et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: Thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis & Rheumatism. 2009; 60(11): 3346-3355. doi: 10.1002/art.24879
92. Body J., Gaich G., Scheele W. et al. A Randomized Double-Blind Trial to Compare the Efficacy of Teriparatide [Recombinant Human Parathyroid Hormone (1-34)] with Alendronate in Postmenopausal Women with Osteoporosis. The Journal of Clinical Endocrinology & Metabolism. 2002; 87(10): 4528-4535. doi: 10.1210/jc.2002-020334.
93. Hadji P, Zanchetta J, Russo L et al. Effect of teriparatide compared with risedronate on back pain and incident vertebral fractures in postmenopausal women with osteoporotic vertebral fractures. Bone. 2011; 48: S82-S83. doi: 10.1016/j.bone.2011.03.108.
94. Miller P.D., Shergy W.J., Body J., Chen P., Rohe M.E, Krege J.H.: Longterm reduction of back pain risk in women with osteoporosis treated with teriparatide compared with alendronate. J Rheumatology. 2005; 32: 1556-1562.
95. European Medicines Agency Press Office. EMEA recommends changes in the product Information for Protelos/ Osseor due to the risk of severe hypersensitivity reactions. EMEA/417458/2007
96. European Medicines Agency: Recommendation to restrict the use of Protelos/Osseor (strontium ranelate) 25 April 2013 EMA/258269/2013
97. European Medicines Agency: Protelos/Osseor (strontium ranelate) to remain available but with futher restrictions 15 April 2014 EMA 235924/2014
98. Lee H., Lie D., Lim K., Thirumoorthy T., Pang S. Strontium ranelate-induced toxic epidermal necrolysis in a patient with post-menopausal osteoporosis. Osteoporosis International. 2008; 20(1): 161-162. doi: 10.1007/s00198-008-0677-0.
99. Tan K.-W., Wang Y.-S., Tay Y.-K.: Stevens-Johnson syndrome due to strontium ranelate. Annals Academy of Medicine. 2011(40): 10-11.
100. Cacoub P., Descamps V., Meyer O., Speirs C., Belissa-Mathiot P., Musette P. Drug rash with eosinophilia and systemic symptoms (DRESS) in patients receiving strontium ranelate. Osteoporosis International. 2013; 24(5): 1751-1757. doi: 10.1007/s00198-013-2265-1
101. Adler R., El-Hajj Fuleihan G., Bauer D. et al. Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2016; 31(1): 16-35. doi: 10.1002/jbmr.2708
102. Bone H.G., Hosking D., Devogelaer J.P., Tucci J.R., Emkey R.D., Tonino R.P., Rodriguez-Portales J.A., Downs R.W., Gupta J., Santora A.C., Liberman U.A.; AlendronatePhase III Osteoporosis Treatment Study GroupTen years' experience with alendronate for osteoporosis in postmenopausal women.N Engl J Med. 2004 Mar 18; 350(12): 1189-99
103. Bone H.G., Brandi M.L., Brown J.P., Chapurlat R., Cummings S.R., Czerwinski E., Fahrleitner-Pammer A., Kendler D.L., Lippuner K., Reginster J.-Y., Roux C., Vittinghoff E., Daizadeh N.S., Wang A., Dakin P., Wagman R.B., Papapoulos S. Ten Years of Denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM extension trial. ASBMR 2015 Abstract (Pub ID: 057237)
104. Brown J., Roux C., Törring O. et al. Discontinuation of denosumab and associated fracture incidence: Analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) Trial. J Bone Miner Res. 2013; 28(4): 746-752. doi: 10.1002/jbmr.1808.
105. Popp A., Zysset P., Lippuner K. Rebound-associated vertebral fractures after discontinuation of denosumab - from clinic and biomechanics. Osteoporosis International. 2015; 27(5): 1917-1921. doi: 10.1007/s00198-015-3458-6.
106. Koldkjær Sөlling A, Harslөf T., Kaal A., Rejnmark L., Langdahl B. Hypercalcemia after discontinuation of longterm denosumab treatment. Osteoporosis International. 2016. doi: 10.1007/s00198-016-3535-5 № 3/2016 Остеопороз и остеопатии
107. Diez-Perez A., Adachi J.D., Agnusdei D., Bilezikian J.P., Compston J.E., Cummings S.R., Eastell R., Eriksen E.F., Gonzales-Macies J., Liberman U.A., Wahl D.A., Seeman E., Kanis J.A., Cooper C.: Treatment failure in osteoporosis. Osteoporosis Int. 2012; (23): 2769-2774.
108. Harris S.T., Watts N.B., Genant H.K. et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA. 1999; 282: 1344-1352.
109. Reginster J., Minne H., Sorensen O. et al. Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis. Osteoporosis International. 2000; 11(1): 83-91. doi: 10.1007/s001980050010.
110. Ettinger B., Black D., Mitlak B. et al. Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With Raloxifene: Results From a 3-Year Randomized Clinical Trial. Obstetrical & Gynecological Survey. 2000; 55(1): 39. doi: 10.1097/00006254-200001000-00021
111. Neer R., Arnaud C., Zanchetta J. et al. Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women With Osteoporosis. N Engl J Med. 2001 May 10; 344(19): 1434-41 DOI: 10.1056/NEJM200105103441904
112. Chesnut C., Skag A., Christiansen C. et al. Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis. J Bone Miner Res. 2004; 19(8): 1241-1249. doi: 10.1359/jbmr.040325.
113. Meunier P., Roux C., Seeman E. et al. The Effects of Strontium Ranelate on the Risk of Vertebral Fracture in Women With Postmenopausal Osteoporosis. N Engl J Med. 2004 Jan 29; 350(5): 459-68 DOI: 10.1056/NEJMoa022436
114. Gaal J., Bender T., Varga J. et al. Overcoming resistance to bisphosphonates through the administration of alfacalcidol: results of a 1-year, open follow-up study. Rheumatol Int. 2009; 30(1): 25-31. doi: 10.1007/s00296-009-0892-9.
115. British Orthopaedic Association and British Geriatrics Society. The care of patients with fragility fracture. 2007: 15-50.
116. Griffiths R., Alper J., Beckingsale A. et al. Management of proximal femoral fractures 2011. Anaesthesia. 2011; 67(1): 85-98. doi: 10.1111/j.1365-2044.2011.06957.x.
117. Загородний Н.В., Голухов Г.Н., Волна А.А. и др. Диагностика и лечение переломов проксимального отдела бедра у лиц пожилого и старческого возраста. Метод. Рекомендации. Москва, РУДН, 2012.
118. Roche J. Effect of comorbidities and postoperative complications on mortality after hip fracture in elderly people: prospective observational cohort study. BMJ. 2005; 331(7529): 1374-0. doi: 10.1136/bmj.38643.663843.55.
119. Kates S., Mendelson D., Friedman S. Co-managed care for fragility hip fractures (Rochester model). Osteoporosis International. 2010; 21(S4): 621-625. doi: 10.1007/s00198-010-1417-9.
120. Agnelli G. Prevention of Venous Thromboembolism in Surgical Patients. Circulation. 2004; 110(24_suppl_1): IV-4-IV-12. doi: 10.1161/01.cir.0000150639.98514.6c.
121. Leonardsson O., Rolfson O., Hommel A., Garellick G., Âkesson K., Rogmark C. Patient-Reported Outcome After Displaced Femoral Neck Fracture. The Journal of Bone and Joint Surgery (American). 2013; 95(18): 1693. doi: 10.2106/jbjs.l.00836.
122. Silverman S.L., Kupperman E.S., Bukata S.V., Members of IOF Fracture Working Group Fracture healing: a consensus report from the International Osteoporosis Foundation Fracture Working Group Osteoporos Int (2016) 27: 2197-2206 DOI 10.1007/s00198-016-3513-y
Review
For citations:
Melnichenko G.A., Belaya Zh.E., Rozhinskaya L.Ya., Grebennikova T.A., Pigarova E.A., Toroptsova N.V., Nikitinskaya O.A., Farba L.Ya., Tarbaeva N.V., Chernova T.O., Dzeranova L.K., Ilyin A.V., Yureneva S.V., Kryukova I.V., Mamedova E.O., Biryukova E.V., Zagorodny N.V., Rodionova S.S., Lesniak O.M., Skripnikova I.A., Dreval A.V., Alekseeva L.A., Dedov I.I. SUMMARY OF CLINICAL GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF OSTEOPOROSIS OF THE RUSSIAN ASSOCIATION OF ENDOCRINOLOGISTS. Osteoporosis and Bone Diseases. 2016;19(3):28-36. (In Russ.) https://doi.org/10.14341/osteo2016328-36
Views:
1100
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
